Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. [electronic resource]
Producer: 20170926Description: 2326-2338 p. digitalISSN:- 1558-8238
- Active Transport, Cell Nucleus
- Androgen Receptor Antagonists -- pharmacology
- Animals
- Antineoplastic Agents, Hormonal -- pharmacology
- Benzamides
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Drug Resistance, Neoplasm
- Drug Synergism
- HEK293 Cells
- Humans
- Inhibitory Concentration 50
- Male
- Metribolone -- pharmacology
- Mice, Inbred NOD
- Mice, SCID
- Nitriles
- Phenylthiohydantoin -- analogs & derivatives
- Prostatic Neoplasms, Castration-Resistant -- drug therapy
- Protein Binding
- Receptors, Androgen -- metabolism
- Steroid 17-alpha-Hydroxylase -- antagonists & inhibitors
- Testosterone -- pharmacology
- Transcriptional Activation -- drug effects
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.